Ely.20 had, in this study, eight out of 38 patients again U more than two treatment cycles, and seven 5-alpha-reductase patients had again U no prior systemic therapy. In addition, there were only five patients with thymic carcinoma, and the extrathoracic disease was in a minority of the F Ll. In a Phase II study of pemetrexed four reactions were observed in patients with thymoma of 23 evaluable patients. TTP and OS were 45.4 and 5.1 weeks in patients with thymoma and thymic carcinoma, respectively.4 Our results are comparable with this series, in which patients had baseline characteristics Similar to our patients. In our study, despite the heterogeneity t in terms of histology, prior therapy and Pr Presentation we showed a significant influence on the results on the basis of histology and site of disease.
Patients with thymic carcinoma have advanced a worse prognosis than patients with thymoma, 21 but it is interesting to note the difference in patients whose disease is far demonstrate. This study shows that the position of the intrathoracic disease is more favorable than the cave site of disease au OUTSIDE the Brusth. Thymoma tends to remain localized in the chest for a long time and rarely metastatic extrathoracic organs. Location and spread to the lung pleura to a sp Later time, are the hours Ufigsten manifestations of thymoma progression.21 In contrast, thymic carcinoma more aggressive and tends to metastasize to extrathoracic organs more frequently.22 treatment with belinostat was good tolerated, and only a few patients ben saturated dose reductions.
QTcprolongation was the reason for dose reduction in three patients, but it was not symptomatic and require no treatment. Kardiotoxizit was t an important negative impact in this class of agents, particularly with depsipeptide.23 During the follow-up studies with belinostat, should be a ridiculed Ngertes QTc should be monitored closely. We examined a number of pharmacodynamic markers to identify patients who are the largest Get Greatest benefits from treatment with HDAC inhibitors can k. HDAC inhibitors induce hyperacetylation of over 100 proteins, we have multiparameter flow cytometry, wherein the protein acetylation world popular t as histone acetylation.11 All patients showed protein and tubulin hyperacetylation in PBMC at day 3 detects time. Unfortunately was not correlated with hyperacetylation response, TTP or OS.
Treg suppressor function in response to HDAC inhibitors in vitro and in vivo in M Nozzles and improved in vitro in humans.13 Recently, it was observed that human Tregs ph Notypisch and functionally different. Expression as a marker for increased ofHLA DRhas Described hte Treg suppressive function. Both ex vivo and in vitro generated HLA-DR isolated Tregs effective in suppressing the immune response of HLA-DR Tregs.24 In our study, most patients, the expression of HLA-DR in the Bev Lkerung erh Ht Treg. It is of interest to our finding of a correlation between the number of Treg with high characteristics of patients with poor prognosis and shorter TTP. We also showed evidence Changes in the Road Transport PlGF FGF and b after treatment with belinostat and an association of more than VEGF and FGF b levels with a poor prognosis sign